Skye Bioscience Announces Resignation Of CFO John Sharp Effective September 8; Appoints CEO Punit Dhillon As Principal Financial And Accounting Officer
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001516551/000162828026061558/skye-20260908.htm
Stocks · News reference
Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Skye Bioscience, Inc. (SKYE)
Filed: 2026-09-11 AccNo: 0001628280-26-061558 Size: 154 KB Item 1.02: Termination of a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the "Company"), with the U.S. Securities and Exchange